Comparing SG&A Expenses: Pfizer Inc. vs Madrigal Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals, the Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. Over the past decade, Pfizer Inc. and Madrigal Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses.

From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's robust operational strategies and market presence. In contrast, Madrigal Pharmaceuticals has seen a dramatic increase in SG&A expenses, skyrocketing by over 600% from 2014 to 2023. This surge indicates Madrigal's aggressive expansion and investment in market penetration.

These trends highlight the different growth strategies of a pharmaceutical giant versus a rising star, offering valuable insights into their financial health and market strategies.